On this page
Fluocinolone Acetonide
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Fluocinolone Acetonide | .25 mg/g | 1191310 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Corticosteroid Hormone Receptor Agonists [MoA] | MoA | All 215 members |
| Corticosteroid [EPC] | EPC | All 215 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 088168-001 | FLUOCINOLONE ACETONIDE | OINTMENT | FLUOCINOLONE ACETONIDE | Prescription | AT |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 5 | Manufacturing (CMC) | Approved | March 7, 1996 | — |
| Supplement | 2 | Manufacturing (CMC) | Approved | March 9, 1988 | — |
| Supplement | 4 | Manufacturing (CMC) | Approved | May 28, 1987 | — |
| Supplement | 3 | Manufacturing (CMC) | Approved | May 28, 1987 | — |
| Original application | 1 | Approved | December 16, 1982 | — |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260223). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE: Fluocinolone Acetonide ointment is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Fluocinolone Acetonide Ointment is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. In hairy sites, the hair should be parted to allow direct contact with the lesion. Occlusive dressing may be used for the management of psoriasis or recalcitrant conditions. Some plastic films may be flammable and due care should be exercised in their use. Similarly, caution should be employed when such films are used on children or left in their proximity, to avoid the possibility of accidental suffocation. If an infection develops, the use of the occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS: Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: Burning Hypertrichosis Maceration of the skin Itching Acneiform eruptions Secondary infection Irritation Hypopigmentation Skin atrophy Dryness Perioral dermatitis Striae Folliculitis Allergic contact dermatitis Miliaria To report SUSPECTED ADVERSE REACTIONS, contact ANI Pharmaceuticals, Inc. at 1-855-204-1431 or FDA at 1-800-FDA-1088 or www.fda/gov/medwatch.
Description
openFDA Drug LabelingDESCRIPTION: Fluocinolone Acetonide Ointment 0.025% is intended for topical administration. The active component is the corticosteroid Fluocinolone Acetonide USP (Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6α,11β,16α)-. It has an empirical formula of C 24 H 30 F 2 O 6 and a molecular weight of 452.49 (CAS Registry Number 67-73-2). Each gram of the ointment contains 0.25 mg Fluocinolone Acetonide in a base containing White Petrolatum. chemical structure
Overdosage
openFDA Drug LabelingOVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS ) .
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED: Fluocinolone Acetonide Ointment USP, 0.025% 15 gram tubes, NDC 0168-0064-15 60 gram tubes, NDC 0168-0064-60 Store at controlled room temperature 15°-30°C (59°-86°F). Avoid excessive heat. Protect from freezing. E. FOUGERA & CO. A division of Fougera Pharmaceuticals Inc. Melville, New York 11747 I26415G R11/12 #296
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: FLUOCINOLONE ACETONIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 62559-299-15 | 62559-299 | ANI Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (62559-299-15) / 15 g in 1 TUBE | November 16, 2023 |
| 62559-299-60 | 62559-299 | ANI Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (62559-299-60) / 60 g in 1 TUBE | November 16, 2023 |
| 0713-0224-15 | 0713-0224 | Cosette Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (0713-0224-15) / 15 g in 1 TUBE | July 26, 1988 |
| 0713-0224-60 | 0713-0224 | Cosette Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (0713-0224-60) / 60 g in 1 TUBE | July 26, 1988 |
| 0168-0064-15 | 0168-0064 | E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC | 15 g in 1 TUBE (0168-0064-15) | December 16, 1982 |
| 0168-0064-60 | 0168-0064 | E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC | 60 g in 1 TUBE (0168-0064-60) | December 16, 1982 |
| 62559-299 | 62559-299 | ANI Pharmaceuticals, Inc. | — | November 13, 2023 |
| 0713-0224 | 0713-0224 | Cosette Pharmaceuticals, Inc. | — | July 26, 1988 |
| 0168-0064 | 0168-0064 | E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC | — | December 16, 1982 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 12 sections on this page.